Engine Capital filed a 13D targeting PDL BioPharm (PDLI) on Wednesday morning, disclosing a 5.28% stake in the Nevada-based healthcare stock. Engine also disclosed it sent a letter to PDLI's board saying the fund "invested in PDLI because of the significant intrinsic value attributable to...
RA Capital Management leads the pack when it comes to health care stock selection. Since 2008, an equal-weight portfolio of the Boston-based hedge fund's top ten 13F positions would have averaged a 37.05% annual return. So, when RA Capital adds to a position, it pays to investigate....
Billionaire Mori Arkin filed a 13D on Aclaris Therapeutics (ACRS), a development stage microcap biotech company with a promising treatment for common warts. Arkin bought the shares through his personal partnership, "The 1999 Company." In the activist filing he disclosed the following trades: Purchase/SaleSharesPriceDate Running ...
In the investing world, those with superior information usually make the most money. And possibly no group has better information on public companies – and profitably acts on it – than corporate insiders at small-cap biotech and medical technology companies.
Protagonist Therapeutics insiders bought on Tuesday as their company's stock plummeted after preliminary data appeared to cast doubt on Protagonist's (PGTX) key drug. On Monday, the company presented an initial look at preliminary results from the TRANSCEND Ph2 open-label study of PTG-300 (hepcidin...
Myriad Genetics co-founder Walter Gilbert PhD bought $150K of MYGN on Dec. 13 @ $25.60. Gilbert, who won the Nobel Prize for Chemistry in 1980, has a history of Form 4 filings at Myriad dating back to 2006. However, this is the insider's first open market purchase...
Twenty-two minutes after regular market hours closed on July 2, an Orbimed Advisors Form 4 relating to Corvus Pharmaceuticals Inc (CRVS) was posted on the SEC's website. The hedge fund, a 10%+ holder and insider in CRVS, disclosed that between June 27 and July 1 it...
Solid Biosciences' private placement featured investments by an all star list of top biotech institutional investors. Cambridge-based Solid Biosciences (SLDB) trades at 1/3 of its January 2018 IPO value. But based on the A-list biotech investors buying shares in the company's July 26 $60...